RESPROLY
Resproly is a research and development, production and sales of formula and equipment for respiratory inhalation. An integrated enterprise that focuses on multiple clinically demanding treatment areas such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Diabetes, and Parkinson's Disease.
RESPROLY
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2018-01-01
Address:
Zhuhai, Guangdong, China
Country:
China
Website Url:
http://www.resproly.com
Total Employee:
11+
Status:
Active
Total Funding:
38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Mobile Non Scaleable Content Euro Pound Sterling Japanese Yen
Similar Organizations
Grow Fit
Grow Fit is a mobile health companion that uses artificial intelligence.
Healthspring
Healthspring is a personalized healthcare services venture based in Mumbai, India.
Insight Timer
Insight Timer is a meditation app that focuses on health and education.
Pneuma Respiratory
Pneuma Respiratory is a pharmaceutical company that creates digital solutions for respiratory drug delivery.
Teal Bio
Teal Bio offers a respirator system that is designed to be reusable and easily disinfected.
Vapo Health
Vapo Health is a respiratory system health care device developer
Current Employees Featured
Founder
Investors List
Qianhai Fund of Funds
Qianhai Fund of Funds investment in Series B - Resproly
Fuho Capital
Fuho Capital investment in Series B - Resproly
CAS Investment Management
CAS Investment Management investment in Series B - Resproly
Shenzhen Yanghe Biopharmaceutical Industry Investment
Shenzhen Yanghe Biopharmaceutical Industry Investment investment in Series A - Resproly
Zhuhai Gree Financial Investment Management
Zhuhai Gree Financial Investment Management investment in Series A - Resproly
Huaige Capital
Huaige Capital investment in Series A - Resproly
Official Site Inspections
http://www.resproly.com
- Host name: 157.255.137.40
- IP address: 157.255.137.40
- Location: China
- Latitude: 23.1167
- Longitude: 113.25
- Timezone: Asia/Shanghai
More informations about "Resproly"
Resproly
瑞思普利是一家专注于呼吸系统吸入给药配方技术及装置研发、生产、销售为一体的综合性企业，公司拥有定量吸入气雾剂（MDI）、干粉吸入剂（DPI）雾化吸入剂（Nebulizer）、鼻喷雾 …See details»
Shenzhen Resproly Biophaemaceutical Co.,Ltd.
Jun 30, 2021 · Resproly is a comprehensive enterprise focusing on the research and development, production and sales of respiratory system inhalation drug formulation technology and devices. The company has metered inhalation …See details»
Company Profile - Shenzhen Resproly …
Resproly is a comprehensive enterprise focusing on the research and development, production and sales of respiratory system inhalation drug formulation technology and devices. The company has metered inhalation …See details»
Resproly - Crunchbase Company Profile & Funding
Resproly is a research and development, production and sales of formula and equipment for respiratory inhalation. An integrated enterprise that focuses on multiple clinically demanding …See details»
Resproly Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Resproly. Use the PitchBook Platform to explore the full profile.See details»
Resproly - Products, Competitors, Financials, Employees, …
Founded in 2018, Resproly specialises in the R&D and production of inhalation therapy, inhaled drugs, and related medical devices. Its offerings focus on the treatment of asthma, chronic …See details»
Shenzhen Resproly Biopharmaceutical Co., Ltd - Patsnap
Explore Shenzhen Resproly Biopharmaceutical Co., Ltd with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, Disease Domain:Immune System Diseases, Technology …See details»
Company news - Shenzhen Resproly Biophaemaceutical Co.,Ltd.
On February 26, Dr. Chen Yongqi, Chairman and Chief Scientist of Resproly, participated in the high-level talent exchange meeting in Hengqin New Area. Starting from the recent Isra... On …See details»
Resproly - Funding, Financials, Valuation & Investors - Crunchbase
Resproly is a respiratory system inhalation therapy and device developer.See details»
Yongqi Chen - Founder, Chairman & Chief Scientific Officer
Yongqi Chen is the Founder, Chairman & Chief Scientific Officer at Resproly. Resproly Founder, Chairman & Chief Scientific Officer. Related Hubs. Edit Related Hubs Section. Hub Name . CB …See details»
Resproly - VentureRadar
Website: http://www.resproly.com/ Develops and produces inhalation drug formulation technology and devices for respiratory conditions, focusing on innovation and quality for global health. …See details»
Resproly Raises over CNY 100 Mn in Series B+ Financing Round
May 5, 2022 · Inhalation Formulation Developer Resproly (Chinese: 瑞思普利) recently received over CNY 100 million (USD 15.14 million) from Qianhai FOF and Fuho Capital in Series B+ …See details»
Shenzhen Resproly Biophaemaceutical Co.,Ltd.
Recently, Israel has developed the anti-coronavirus inhalation preparation EXO-CD24, which has attracted widespread attention in the industry. The exosomal biological preparation can …See details»
Resproly inhales $31m in series B round - Global Venturing
Feb 3, 2021 · Resproly, a China-based developer of inhalation-focused therapeutics and medical devices that counts corporates Shanghai Kindly Enterprise Development and Gree as …See details»
Resproly - Contacts, Employees, Board Members, Advisors & Alumni
Resproly has 1 current employee profile, Founder, Chairman & Chief Scientific Officer Yongqi Chen. Resproly is a respiratory system inhalation therapy and device developer.See details»
RSN-0402 - Drug Targets, Indications, Patents - Synapse
RSN-0402, Initially developed by Shenzhen Resproly Biopharmaceutical Co., Ltd, Now, its global highest R&D status is Phase 1, Therapeutic Areas: Respiratory Diseases,Other Diseases, …See details»
重磅积极信号，IPF有望进入吸入治疗时代！ - Resproly
Aug 14, 2024 · “瑞思普利”是由深耕吸入制剂多年的，回国跨国企业首席科学家陈永奇博士创立的一家专注于呼吸系统吸入给药配方技术及装置研发的制药企业，拥有约1万平米的研发及满足 …See details»
Resproly completes 50 million yuan A round of financing and …
Respley is a R&D-driven company that takes high-end imitations of blockbuster drugs in the respiratory system field as its entry point; uses years of mainstream product research and …See details»
瑞思普利顺利召开2020年度表彰大会 - 深圳瑞 ... - Resproly
2月3日，瑞思普利举行了简单而又隆重的2020年度表彰大会，大会由副总经理华丽博士主持，陈永奇董事长、韩飞副总经理及全体员工出席了本次表彰大会，大会对为公司做出卓越贡献的个人 …See details»
Hikma disrupted the US$3.5 billion Seretide® inhaler, Vectura …
A few days ago, Hikma issued an announcement stating that its company's salmeterol and ticasone inhalation powder aerosols (specifications: 100mcg/50mcg and 250mcg/50mcg) …See details»